Aprepitant for refractory nivolumab-induced pruritus

Lung Cancer

Volumn 109, Issue , 2017, Pages 58-61

  Ito, Jiro ^a   Fujimoto, Daichi ^a   Nakamura, Ayaka ^a   Nagano, Tohru ^a   Uehara, Keiichiro ^a   Imai, Yukihiro ^a   Tomii, Keisuke ^a  

^a KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

aprepitant; immune checkpoint inhibitors; immune related adverse events; nivolumab; pruritus; Stevens Johnson syndrome

Indexed keywords

ANTIHISTAMINIC AGENT; APREPITANT; EMOLLIENT AGENT; ERLOTINIB; GEFITINIB; NIVOLUMAB; PEMETREXED; PREDNISOLONE; STEROID; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR ANTAGONIST; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DERMATITIS; DISEASE SEVERITY; EMERGENCY WARD; EPIDERMIS; FACE ERYTHEMA; FEMALE; FEVER; HISTOLOGY; HOSPITAL DISCHARGE; HUMAN; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LUNG ADENOCARCINOMA; LYMPHOCYTIC INFILTRATION; MACULOPAPULAR RASH; MUCOSA; MULTIPLE CYCLE TREATMENT; ODYNOPHAGIA; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PRURITUS; RASH; SKIN BIOPSY; SKIN EDEMA; SKIN NECROSIS; SLEEP DISORDER; STEROID THERAPY; STEVENS JOHNSON SYNDROME; TOPICAL TREATMENT; TREATMENT DURATION; VISUAL ANALOG SCALE; IMMUNOLOGY; IMMUNOTHERAPY; JAPAN; LUNG TUMOR; NON SMALL CELL LUNG CANCER; PROCEDURES; REMISSION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOTHERAPY; JAPAN; LUNG NEOPLASMS; MORPHOLINES; NEUROKININ-1 RECEPTOR ANTAGONISTS; PROGRAMMED CELL DEATH 1 RECEPTOR; PRURITUS; REMISSION INDUCTION; STEVENS-JOHNSON SYNDROME;

EID: 85018373866     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2017.04.020     Document Type: Article

References (14)

1. [1] Naidoo, J., Page, D.B., Li, B.T., et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol. 26 (2015), 2375–2391.
2. [2] Stander, S., Siepmann, D., Herrgott, I., Sunderkotter, C., Luger, T.A., Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One, 5, 2010, e10968.
3. [3] Rzany, B., Hering, O., Mockenhaupt, M., et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br. J. Dermatol. 135 (1996), 6–11.
4. [4] Dalgard, F., Lien, L., Dalen, I., Itch in the community: associations with psychosocial factors among adults. J. Eur. Acad. Dermatol. Venereol. 21 (2007), 1215–1219.
5. [5] Santini, D., Vincenzi, B., Guida, F.M., et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol. 13 (2012), 1020–1024.
6. [6] Vincenzi, B., Fratto, M.E., Santini, D., Tonini, G., Aprepitant against pruritus in patients with solid tumours. Support. Care Cancer 18 (2010), 1229–1230.
7. [7] Vincenzi, B., Tonini, G., Santini, D., Aprepitant for erlotinib-induced pruritus. N. Engl. J. Med. 363 (2010), 397–398.
8. [8] Mir, O., Blanchet, B., Goldwasser, F., More on aprepitant for erlotinib-induced pruritus [Letter]. N. Engl. J. Med., 364, 2011, 487.
9. [9] Booken, N., Heck, M., Nicolay, J.P., Klemke, C.D., Goerdt, S., Utikal, J., Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Br. J. Dermatol. 164 (2011), 665–667.
10. [10] Duval, A., Dubertret, L., Aprepitant as an antipruritic agent?. N. Engl. J. Med. 361 (2009), 1415–1416.
11. [11] Torres, T., Fernandes, I., Selores, M., Alves, R., Lima, M., Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues. J. Am. Acad. Dermatol. 66 (2012), e14–e15.
12. [12] Ladizinski, B., Bazakas, A., Olsen, E.A., Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 67 (2012), e198–199.
13. [13] Jimenez-Gallo, D., Albarran-Planelles, C., Linares-Barrios, M., Fernandez-Anguita, M.J., Marquez-Enriquez, J., Rodriguez-Mateos, M.E., Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant. Dermatol. Ther. 27 (2014), 178–182.
14. [14] Borja-Consigliere, H.A., Lopez-Pestana, A., Vidal-Mancenido, M.J., Tuneu-Valls, A., Aprepitant in the treatment of refractory pruritus secondary to cutaneous T-cell lymphoma. Actas Dermosifiliogr. 105 (2014), 716–718.